Evotec SE announced today that the Company has reached another programme designation within its neuroscience collaboration with Bristol Myers Squibb triggering a payment of US$ 16 m to Evotec. The programme further adds to a fast-growing pipeline in neurodegeneration that also includes EVT8683, which entered clinical development end of 2021.
